← Back to Search

Dietary Supplement

Nicotinamide mononucleotide (NMN-C) for Healthy Subjects

N/A
Waitlist Available
Research Sponsored by Seneque SA
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 hour post-dose on day 29
Awards & highlights

Summary

This trial studies the safety and effects of NMN-C, a compound that may improve energy and cell health, in healthy adults aged 18-65 over a month.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 hour post-dose on day 29
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 hour post-dose on day 29 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Safety as measured by subject incident of treatment-emergent adverse events
Safety as measured by subject incident of treatment-emergent clinically significant changes in clinical laboratory safety tests.
Safety as measured by subject incident of treatment-emergent clinically significant changes in vital signs
Secondary study objectives
Change from baseline in NAD+ and NMN concentrations in whole blood
Change from baseline in NAD+ metabolites concentrations in plasma
Change from baseline in NAD+ metabolites concentrations in urine
+7 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: NMN-CExperimental Treatment1 Intervention
Healthy individuals receiving NMN-C
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nicotinamide mononucleotide (NMN-C)
2021
N/A
~50

Find a Location

Who is running the clinical trial?

Seneque SALead Sponsor
3 Previous Clinical Trials
237 Total Patients Enrolled
Dicentra Inc.Industry Sponsor
4 Previous Clinical Trials
384 Total Patients Enrolled
LGDIndustry Sponsor
6 Previous Clinical Trials
449 Total Patients Enrolled
~6 spots leftby Sep 2025